诺和诺德：更多美国医保患者偏好GLP-1口服药
2026-06-24 18:30:16
据彭博社报道，诺和诺德表示，其市场调研显示，美国Medicare受益人中偏好减重口服药而非注射的人数是后者的两倍。该丹麦制药商称将利用这一偏好，从竞争对手礼来公司手中争夺市场份额。
Disclaimer:
1. The information provided does not constitute investment advice. Investors should make independent decisions and bear all risks themselves.
2. The copyright of this content belongs to the original author. The views expressed herein are solely those of the author and do not represent the stance or position of this website.
Previous article：
SBI VC Trade在日本上线RLUSD
